|
Market Closed -
NSE India S.E.
15:05:10 06/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,860.00 INR | +1.69% |
|
+5.62% | +8.16% |
| 11-04 | India proposes instant manufacturing licence suspension for drugs failing quality tests | RE |
| 11-02 | Indian shares set for positive start on talks to end Iran war, strong Reliance earnings | RE |
| Market Cap | 4,463B 47.48B 42.58B 38.91B 35.52B 66.93B 69.04B 469B 187B 2,381B 178B 174B 7,517B | P/E 2027 * |
36.3x | P/E 2028 * | 29.8x |
|---|---|---|---|---|---|
| Enterprise Value | 4,167B 44.33B 39.76B 36.33B 33.17B 62.49B 64.46B 438B 175B 2,223B 166B 163B 7,019B | EV / Sales 2027 * |
6.43x | EV / Sales 2028 * | 5.66x |
| Free-Float |
44.39% | Yield 2027 * |
0.89% | Yield 2028 * | 1.05% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +1.69% | ||
| 1 week | +5.62% | ||
| Current month | +4.63% | ||
| 1 month | +4.51% | ||
| 3 months | -4.12% | ||
| 6 months | +2.15% | ||
| Current year | +8.16% |
| 1 week | 1,722 |  | 1,868.9 |
| 1 month | 1,719.1 | | 1,868.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,583.7 | | 2,046.9 |
| 3 years | 1,146.55 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 71 | 21/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.69% | +5.62% | +10.06% | +63.00% | 46.44B | |
| -0.79% | -1.43% | +46.25% | +138.46% | 1,216B | |
| +1.43% | +0.37% | +48.51% | +82.52% | 656B | |
| +1.07% | +0.18% | +34.39% | +105.99% | 509B | |
| -0.36% | -2.84% | +47.23% | +64.51% | 384B | |
| -0.14% | +0.27% | +73.87% | +41.93% | 362B | |
| -0.78% | +0.59% | +31.01% | +59.68% | 311B | |
| -0.80% | +6.73% | +11.89% | +35.64% | 293B | |
| +0.03% | -0.07% | +43.94% | +70.61% | 249B | |
| -0.41% | +0.77% | +36.15% | +104.55% | 208B | |
| Average | +0.09% | +0.93% | +38.33% | +76.69% | 423.42B | |
| Weighted average by Cap. | -0.03% | +0.08% | +43.10% | +91.54% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 648B 6.89B 6.18B 5.65B 5.16B 9.72B 10.03B 68.11B 27.16B 346B 25.88B 25.32B 1,092B | 723B 7.69B 6.9B 6.31B 5.76B 10.85B 11.19B 76.03B 30.32B 386B 28.88B 28.26B 1,218B |
| Net income | 122B 1.3B 1.16B 1.06B 969M 1.83B 1.88B 12.8B 5.1B 64.96B 4.86B 4.76B 205B | 150B 1.6B 1.43B 1.31B 1.2B 2.25B 2.32B 15.78B 6.29B 80.12B 6B 5.87B 253B |
| Net Debt | -296B -3.15B -2.82B -2.58B -2.36B -4.44B -4.58B -31.11B -12.4B -158B -11.82B -11.56B -499B | -366B -3.9B -3.5B -3.2B -2.92B -5.5B -5.67B -38.52B -15.36B -196B -14.63B -14.32B -617B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/11/26 | ₹1,860.00 | +1.69% | 2,348,251 |
| 05/11/26 | ₹1,829.00 | +3.14% | 3,923,834 |
| 04/11/26 | ₹1,773.40 | +0.20% | 4,925,315 |
| 03/11/26 | ₹1,769.90 | -0.01% | 2,646,691 |
| 02/11/26 | ₹1,770.00 | -0.43% | 3,457,791 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
